NSF and renal disease: An overestimated risk?

9^th International Conference on Nephrology: Kidney & Therapeutics

September 29-30, 2016 Orlando, USA

Sadhna Nandwana

Emory University, USA

Scientific Tracks Abstracts: J Nephrol Ther

Abstract :

Review the issue of NSF in renal failure patients with usage of gadolinium based contrast agents (GBCAs) and provide an update of current literature regarding risks of NSF with certain GBCAs. Also, This presentation will discuss the current national/international recommendations and explore eliminating screening of at-risk patients. Presentation will include the timeline of NSF discovery, types of GBCAs, known cases of NSF and current research on commonly used GBCAs in renal impaired patients. Recent landmark papers regarding risk of NSF with gadobenate dimeglumine will be specifically discussed. The controversy of renal failure patients receiving MRIs with contrast will be explored and the risks and benefits will be discussed.

Biography :

Sadhna Nandwana is an Abdominal Imaging Radiologist who began her career at Rush Medical School and completed her Residency at Beth Israel Deaconess Medical Center. Her research endeavors have been in Quality Assurance and Clinical Research. She has several peer-reviewed published articles and has been an invited Lecturer for multiple national and international meetings.

Email: snandwa@emory.edu